Ozempic vs Wegovy vs Rybelsus: What Actually Differs
Ozempic, Wegovy and Rybelsus all contain semaglutide, but they differ in approved uses, doses, shot vs pill, and price. The reformulated Rybelsus tablets were renamed Ozempic tablets on January 30, 2026, and the Rybelsus name is being retired in the US as the Ozempic pill rolls out from May 4, 2026.
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.
Ozempic, Wegovy and Rybelsus all contain the same active ingredient, semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist [1][2][3]. What separates them is the approved use, the form the medicine comes in, the dose schedule, and the price. Ozempic is the type 2 diabetes brand, approved as a once-weekly injection on December 5, 2017 and, since 2026, also available as a daily tablet [4][6]. Wegovy is the weight-management brand, approved as a once-weekly injection on June 4, 2021 and as a daily tablet on December 22, 2025, with the pill reaching pharmacies in early January 2026 [5][7]. Rybelsus, the original oral semaglutide for type 2 diabetes approved on September 20, 2019, saw its reformulated 1.5 mg, 4 mg and 9 mg tablets rebranded as Ozempic tablets on January 30, 2026 [4]. Novo Nordisk is now retiring the Rybelsus name in the US, with the Ozempic pill rolling out from May 4, 2026 and the rebrand proceeding over the year [6][11]. Rybelsus continues to be marketed outside the US [6][11].
What are the semaglutide brand names in the US?
There are now two surviving US brand names for semaglutide: Ozempic and Wegovy [4][5]. Each comes in two forms. Ozempic is available as an injection and as tablets, both approved for adults with type 2 diabetes [1][3][4]. Wegovy is available as an injection and as tablets, both approved for weight management and cardiovascular risk reduction in adults with obesity or overweight [2][5][7].
Rybelsus was the third brand name. It was the first GLP-1 medicine to come in a tablet form when the FDA approved it on September 20, 2019, in 3 mg, 7 mg and 14 mg strengths [4][11]. Novo Nordisk has since retired the Rybelsus name in the US and moved the tablets under the Ozempic brand [6][11].
When was each product approved?
The approvals stacked up over about eight years:
- Ozempic injection was first approved on December 5, 2017 for type 2 diabetes. The cardiovascular risk indication followed on January 16, 2020, the 2 mg dose on March 28, 2022, and the chronic kidney disease indication on January 28, 2025 [4].
- Rybelsus tablets (3 mg, 7 mg, 14 mg) were approved on September 20, 2019 [4].
- Wegovy injection was approved on June 4, 2021 for adults, extended to teens aged 12 and older on December 23, 2022, then to cardiovascular risk reduction on March 8, 2024, to MASH (metabolic dysfunction-associated steatohepatitis) under accelerated approval on August 15, 2025, and to the higher-dose Wegovy HD 7.2 mg on March 19, 2026 [5].
- A reformulated oral semaglutide in 1.5 mg, 4 mg and 9 mg strengths was approved on December 9, 2024 and rebranded as Ozempic tablets on January 30, 2026 [4]. Wegovy tablets were approved on December 22, 2025 [4][5][7].
What is Ozempic approved for?
Ozempic injection carries three indications, all in adults with type 2 diabetes: improving glycemic control as an adjunct to diet and exercise; reducing the risk of major adverse cardiovascular events (MACE) in adults with established cardiovascular disease; and reducing the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with chronic kidney disease [1][4]. Novo Nordisk’s January 28, 2025 approval announcement, relayed by Drugs.com, described Ozempic as the only GLP-1 RA approved to reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease [4].
Ozempic tablets carry two indications: glycemic control in adults with type 2 diabetes, and MACE risk reduction in adults with type 2 diabetes at high risk for these events [3][4]. Neither Ozempic injection nor Ozempic tablets are approved for use in children [6].
The injection starts at 0.25 mg once weekly for 4 weeks, then moves to 0.5 mg. If more glycemic control is needed, the dose can go to 1 mg and then 2 mg, each after at least 4 weeks. For the chronic kidney disease indication, the label directs an increase to 1 mg [1]. Pens come as 2 mg/3 mL, 4 mg/3 mL and 8 mg/3 mL multi-dose pens, and 0.25 mg, 0.5 mg and 1 mg single-dose prefilled syringes [1].
What is Wegovy approved for?
Wegovy injection is indicated, along with a reduced calorie diet and increased physical activity, for three uses: reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight; long-term weight reduction in adults and children aged 12 and older with obesity, and in adults with overweight plus at least one weight-related comorbidity; and treatment of noncirrhotic MASH with moderate to advanced fibrosis (stages F2 to F3) in adults, under accelerated approval [2][5].
The injection escalates over 16 weeks: 0.25 mg for weeks 1 to 4, 0.5 mg for weeks 5 to 8, 1 mg for weeks 9 to 12, and 1.7 mg for weeks 13 to 16, with maintenance from week 17 at 2.4 mg (the recommended dose) or 1.7 mg [2].
Wegovy HD, a 7.2 mg injection approved on March 19, 2026, is for adults with obesity who have tolerated the 2.4 mg dose for at least 4 weeks and for whom additional weight reduction is clinically indicated; it became available in April 2026 [8]. In the 72-week STEP UP trial of 1,407 adults with obesity and without diabetes, average weight loss if all patients stayed on treatment (the efficacy estimand) was 20.7% on 7.2 mg versus 17.5% on 2.4 mg and 2.4% on placebo, and 31.2% versus 15.3% and 0% respectively lost 25% or more of body weight [8]. Events related to altered skin sensation were reported by 22% of the 7.2 mg group versus 6% on 2.4 mg and 0.3% on placebo [8].
What happened to the Rybelsus name in the US?
Novo Nordisk is retiring the Rybelsus brand in the US and moving its tablets under the Ozempic name. Ed Cinca, Novo’s senior vice president of marketing and patient solutions, said the Rybelsus brand would not be carried forward but the tablets would continue under the Ozempic brand, with the campaign tagline “There is only one Ozempic” [11]. The change was first announced in February 2026, the Ozempic pill began rolling out on May 4, 2026, and Cinca said the rebranding will be approached over the year [11]. The rebrand is US-only; Rybelsus continues to be marketed outside the US [6][11].
The Ozempic pill is not simply Rybelsus with a new label. The original 3 mg, 7 mg and 14 mg tablets were reformulated into a smaller tablet with a new coating and improved bioavailability, now sold as Ozempic tablets in 1.5 mg, 4 mg and 9 mg strengths. Novo states the new pill works similarly to the original strengths and has the same efficacy and safety profile [6][11]. The label states the two products are not substitutable on a mg-to-mg basis [3].
Ozempic tablets became available on May 4, 2026 at more than 70,000 US pharmacies and are made end-to-end in the US [6][11]. Novo has also filed a supplemental application for Ozempic tablets 25 mg for type 2 diabetes, with an FDA decision expected by the end of 2026 [6].
How do you switch from Rybelsus to the Ozempic pill?
Novo advises current Rybelsus patients to continue their medication as directed and speak with their healthcare professional about transitioning to the Ozempic pill, as appropriate [6][11]. The label fills in the mechanics: no switching between Rybelsus and Ozempic tablets during the first 30 days of treatment. After 30 days, patients may switch by starting the other tablet product the day after discontinuing the previous one, with Rybelsus 14 mg corresponding to Ozempic tablets 9 mg, and the Rybelsus 3 mg and 7 mg strengths corresponding to 1.5 mg and 4 mg [3][11].
Patients taking the 0.5 mg dose of Ozempic injection may switch to Ozempic tablets, starting 4 mg or 9 mg one week after the last injection [3].
How is each product taken?
The injections — Ozempic and Wegovy — go subcutaneously into the abdomen, thigh or upper arm once weekly, on the same day each week, at any time of day, with or without meals [1][2]. If an Ozempic injection dose is missed, it can be given within 5 days [1].
The tablets — Wegovy and Ozempic — are taken once daily in the morning on an empty stomach with up to 4 ounces of water only, swallowed whole, followed by a wait of at least 30 minutes before food, drink or other oral medicines [2][3]. If a Wegovy tablet dose is missed, the label says to skip it and take the next dose the following day [2]. Wegovy tablets are co-formulated with SNAC, an absorption enhancer; semaglutide from the tablet is absorbed mainly in the stomach, and absolute bioavailability is estimated at about 1% to 2% [2]. Breastfeeding is not recommended during treatment with the tablets [2][3].
Is the Ozempic pill the same as the Wegovy pill?
No. Both are oral semaglutide and both start at 1.5 mg, but they are approved for different conditions and top out at different strengths. Ozempic tablets come in 1.5 mg, 4 mg and 9 mg and are approved for type 2 diabetes indications [3]. Wegovy tablets come in 1.5 mg, 4 mg, 9 mg and 25 mg and are approved for weight reduction and cardiovascular risk reduction in adults; it is not known if they are safe and effective in people under 18 [2][7].
Wegovy tablets escalate monthly: 1.5 mg for days 1 to 30, 4 mg for days 31 to 60, 9 mg for days 61 to 90, then 25 mg maintenance from day 91 [2]. The Wegovy pill is approved only in the US and was the first oral GLP-1 for obesity [7]. In the 64-week OASIS 4 trial of 307 adults with obesity or overweight and weight-related comorbidities, without diabetes, average weight loss if all patients stayed on treatment (the trial product estimand) was 16.6% on the 25 mg tablet versus 2.7% on placebo; measured regardless of whether patients stayed on treatment (the treatment policy estimand), it was 13.6% versus 2.4%; and 76% versus 31% lost 5% or more of body weight [7].
The Wegovy label also covers switching between its own forms: patients on the 2.4 mg injection may start 25 mg tablets one week after the last injection, and patients on 25 mg tablets may start the 2.4 mg injection the day after the last tablet [2].
What do these medicines cost?
NovoCare self-pay prices (one month is defined as one bottle of 30 tablets or one box of pens) [9][10]:
| Product | Dose | Self-pay per month |
|---|---|---|
| Ozempic pill | 1.5 mg | $149 [10] |
| Ozempic pill | 4 mg | $199 [10] |
| Ozempic pill | 9 mg | $299 [10] |
| Ozempic pen | 0.25 mg or 0.5 mg | $199 for first 2 months for new patients, then $349 [10] |
| Ozempic pen | 1 mg | $349 [10] |
| Ozempic pen | 2 mg | $499 [10] |
| Wegovy pill | 1.5 mg | $149 [9] |
| Wegovy pill | 4 mg | $199 [9] |
| Wegovy pill | 9 mg | $299 [9] |
| Wegovy pill | 25 mg | $299 [9] |
| Wegovy pen | 0.25 mg or 0.5 mg | $199 for first 2 months for new patients through December 31, 2026, then $349 [9] |
| Wegovy pen | 1 mg, 1.7 mg or 2.4 mg | $349 [9] |
| Wegovy HD pen | 7.2 mg | $399 [9] |
With commercial insurance and a savings offer, patients may pay as little as $25, subject to a maximum savings of $100 per month. Government beneficiaries are excluded, and eligibility and restrictions apply; Novo Nordisk reserves the right to modify or cancel the programs at any time [9][10].
Does the 2027 list price cut change these prices?
No. On February 24, 2026, Novo Nordisk announced that the list price, or wholesale acquisition cost (WAC), of Wegovy injection 2.4 mg and tablets 25 mg, Ozempic injection 0.5 mg, 1 mg and 2 mg, and Rybelsus tablets 7 mg and 14 mg will drop to $675 per month, effective January 1, 2027 [12]. That is a reduction of approximately 50% for Wegovy and 35% for Ozempic from the current list price [12].
Novo states the change does not affect direct-to-patient self-pay prices, such as the NovoCare prices above. The company says the cut is aimed at people whose out-of-pocket costs track the list price, such as those with high-deductible health plans or coinsurance [12].
Which product matches which diagnosis?
The approved label follows the diagnosis. Type 2 diabetes indications sit with Ozempic, in pen or pill form; obesity, overweight and MASH indications sit with Wegovy, in pen or pill form [1][2][3]. Novo describes Wegovy as the only GLP-1 weight-loss medicine indicated to reduce the risk of cardiovascular events in adults with established cardiovascular disease and obesity or overweight [7][8].
The Wegovy label states that Wegovy should not be used with other semaglutide-containing products or with any other GLP-1 receptor agonist, and Novo’s Wegovy materials repeat the same limitation [2][7]. All three products share a boxed warning about the risk of thyroid C-cell tumors, and all are contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2) [1][2][3].
The most common adverse reactions across the products are nausea, vomiting, diarrhea, abdominal pain and constipation; the tablet labels add decreased appetite, and the Wegovy list also includes hair loss and dysesthesia [1][2][3][4]. Which product, dose and form to use is a decision for a prescriber and patient together.
Sources
- Novo Nordisk. Ozempic (semaglutide) injection, for subcutaneous use. Prescribing information.
- Novo Nordisk. Wegovy (semaglutide) injection. Prescribing information.
- Novo Nordisk. Ozempic (semaglutide) tablets and Rybelsus (semaglutide) tablets. Prescribing information.
- Drugs.com. Ozempic FDA Approval History. April 23, 2026.
- Drugs.com. Wegovy FDA Approval History. May 18, 2026.
- PR Newswire. Novo Nordisk’s Ozempic pill, the only FDA-approved oral peptide GLP-1 medication for adults with type 2 diabetes, soon to be available in the US. May 1, 2026.
- PR Newswire. FDA approves Novo Nordisk’s Wegovy pill, the first and only oral GLP-1 for weight loss in adults.
- PR Newswire. FDA approves Novo Nordisk’s new Wegovy HD injection, delivering the highest weight loss to date for a Wegovy injection. March 19, 2026.
- NovoCare. Wegovy price guide.
- NovoCare. Ozempic pill and pen price guide.
- Fierce Pharma. Novo Nordisk’s Rybelsus officially retired in US as ‘Ozempic pill’ takes branding center stage. May 1, 2026.
- PR Newswire. Novo Nordisk announces significant reduction in US list price for Wegovy, Ozempic, and Rybelsus (semaglutide medicines).
Frequently asked questions
Is Rybelsus the same as the Ozempic pill?
Both contain oral semaglutide for type 2 diabetes, but they are not the same product. The Ozempic pill is a reformulated, smaller tablet with a new coating and improved bioavailability, sold in 1.5 mg, 4 mg and 9 mg strengths. The label states Rybelsus and Ozempic tablets are not substitutable on a mg-to-mg basis, though Rybelsus 3, 7 and 14 mg correspond to 1.5, 4 and 9 mg.
Can Ozempic be prescribed for weight loss?
The Ozempic label covers type 2 diabetes: glycemic control, cardiovascular risk reduction, and (for the injection) chronic kidney disease. The weight-management indications — weight reduction in adults and children 12 and older with obesity, and MASH — sit with Wegovy. Novo notes people taking Ozempic may also lose weight, but that is not an approved use.
Is Wegovy just a higher dose of Ozempic?
No. Both contain semaglutide, but the brands carry different approved uses and different dose schedules. Wegovy injection escalates to a 2.4 mg (or 1.7 mg) weekly maintenance dose, with a 7.2 mg Wegovy HD option, while Ozempic injection tops out at 2 mg weekly for type 2 diabetes.
Can you switch from Wegovy injection to the Wegovy pill?
The label allows it for adults on the 2.4 mg injection: start 25 mg tablets one week after the last injection. Going the other way, patients on 25 mg tablets may start the 2.4 mg injection the day after the last tablet.
Why does the pill have to be taken on an empty stomach?
Wegovy tablets are co-formulated with SNAC, an absorption enhancer, and semaglutide from the tablet is absorbed mainly in the stomach, with absolute bioavailability of only about 1% to 2%. The labels direct taking the tablet in the morning with up to 4 ounces of water and waiting at least 30 minutes before food, drink or other oral medicines.
What happens to current Rybelsus prescriptions?
Novo advises Rybelsus patients to continue their medication as directed and speak with their healthcare professional about transitioning to the Ozempic pill, as appropriate. The reformulated tablets were rebranded as Ozempic tablets on January 30, 2026, the Ozempic pill rolled out from May 4, 2026, and the rebrand proceeds over the year; Rybelsus continues to be marketed outside the US.
Is the Ozempic pill the same as the Wegovy pill?
No. Both are oral semaglutide starting at 1.5 mg, but Ozempic tablets (1.5, 4, 9 mg) are approved for type 2 diabetes, while Wegovy tablets (1.5, 4, 9, 25 mg) are approved for weight reduction and cardiovascular risk reduction in adults only.
Does the 2027 list price cut lower the self-pay price?
No. Novo states the reduction of the list price (WAC) to $675 per month, effective January 1, 2027, does not affect direct-to-patient self-pay prices. The cut is aimed at people whose out-of-pocket costs track the list price, such as those with high-deductible plans or coinsurance.
This article summarizes FDA labeling, published research and company information current as of September 14, 2026. It is not medical advice and does not replace a conversation with your own healthcare provider. How we research and verify.